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Neurohormonal pathways are of critical importance in the
pathogenesis and progression of heart failure. Current
heart failure therapies mainly focus on blocking the detri-
mental effects of long-term neurohormonal activation and
largely ignore the physiological compensatory effect of the
natriuretic peptide system and other endogenous vasodila-
tor systems. Natriuretic peptides exert their effects by acti-
vating membrane-bound guanylyl cyclase-coupled
receptors (NPR-A and -B), resulting in increased concen-
trations of the second messenger cyclic guanosine mono-
phosphate (cGMP) [1].
LCZ696 (sacubitril/valsartan) exhibits the novel
mechanism of action of an angiotensin receptor neprilysin
inhibitor (ARNI) by simultaneously inhibiting neprilysin
(neutral endopeptidase; NEP) via LBQ657, the active
metabolite of the prodrug sacubitril (AHU377), and block-
ing the angiotensin II type-1 receptor via valsartan [2].
The cardiovascular effects of LCZ696 in heart failure
patients are attributed to the enhancement of peptides
that are degraded by neprilysin such as natriuretic peptides
by LBQ657 and the simultaneous inhibition of the deleter-
ious effects of angiotensin II by valsartan.
In the PARADIGM-HF study of 8442 patients with
heart failure and reduced ejection fraction (HFrEF),
LCZ696 reduced the primary endpoint of cardiovascular
death or heart failure hospitalization by 20% and reduced
death due to any cause by 16% (both p<0.001) compared
with the ACE-inhibitor enalapril. Symptoms and physical
functioning, as assessed by the Kansas City Cardiomyopa-
thy Questionnaire (patient assessment) and NYHA classifi-
cation (physician assessment), were also favourably
impacted by LCZ696 vs. enalapril. LCZ696 increased levels
of cGMP and BNP while decreasing NT-proBNP and
troponin levels (all p<0.001) [3,4].
LCZ696 is currently under investigation in patients with
heart failure with preserved ejection fraction (HFpEF).
Of note, hypertrophy signalling, diastolic relaxation and
stiffness, and vasorelaxation are favourably modified by
cGMP-dependent protein kinase phosphorylation, sug-
gesting that agents that raise cGMP levels may have a role
in the treatment of HFpEF [5]. In the proof-of-concept
Phase II PARAMOUNT study (n=301), LCZ696 reduced
NT-proBNP (primary endpoint) to a greater extent than
did valsartan at 12 weeks (p<0.01), and was associated
with left atrial reverse remodelling and improvement in
NYHA class at 36 weeks (p<0.05) [6]. The PARAGON
study is a large ongoing Phase III outcomes study
(n=4300) that will clarify the role of LCZ696 in the treat-
ment HFpEF, a condition for which there is currently no
evidence-based therapy [7].
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